News coverage about Alexion Pharmaceuticals (NASDAQ:ALXN) has trended somewhat positive recently, Accern reports. Accern scores the sentiment of media coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Alexion Pharmaceuticals earned a media sentiment score of 0.17 on Accern’s scale. Accern also gave news stories about the biopharmaceutical company an impact score of 48.0684228778746 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

These are some of the news stories that may have impacted Accern Sentiment’s scoring:

Shares of Alexion Pharmaceuticals (NASDAQ:ALXN) opened at $115.17 on Monday. The company has a debt-to-equity ratio of 0.35, a current ratio of 2.96 and a quick ratio of 2.51. The firm has a market capitalization of $25,730.08, a price-to-earnings ratio of 23.55, a PEG ratio of 1.25 and a beta of 1.22. Alexion Pharmaceuticals has a 52-week low of $96.18 and a 52-week high of $149.34.

Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $1.44 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.32 by $0.12. The firm had revenue of $859.00 million during the quarter, compared to analysts’ expectations of $864.34 million. Alexion Pharmaceuticals had a return on equity of 12.55% and a net margin of 14.57%. The business’s quarterly revenue was up 7.5% on a year-over-year basis. During the same quarter last year, the firm earned $1.23 EPS. research analysts expect that Alexion Pharmaceuticals will post 4.81 earnings per share for the current fiscal year.

Several brokerages have recently weighed in on ALXN. Royal Bank Of Canada began coverage on Alexion Pharmaceuticals in a report on Thursday, September 14th. They issued an “outperform” rating and a $161.00 price target on the stock. J P Morgan Chase & Co upgraded Alexion Pharmaceuticals from a “neutral” rating to an “overweight” rating and increased their price target for the stock from $163.00 to $175.00 in a report on Tuesday, September 5th. Deutsche Bank AG reiterated a “buy” rating and issued a $158.00 price target (up from $153.00) on shares of Alexion Pharmaceuticals in a report on Wednesday, September 13th. BMO Capital Markets reiterated an “outperform” rating and issued a $173.00 price target (up from $168.00) on shares of Alexion Pharmaceuticals in a report on Wednesday, September 13th. Finally, SunTrust Banks, Inc. reiterated a “buy” rating and issued a $180.00 price target (up from $170.00) on shares of Alexion Pharmaceuticals in a report on Wednesday, September 13th. Six research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and two have issued a strong buy rating to the company. The stock has an average rating of “Buy” and an average price target of $154.01.

ILLEGAL ACTIVITY NOTICE: This piece was first posted by Daily Political and is the sole property of of Daily Political. If you are viewing this piece on another domain, it was illegally stolen and reposted in violation of US & international copyright legislation. The original version of this piece can be accessed at https://www.dailypolitical.com/2017/11/13/alexion-pharmaceuticals-alxn-given-media-sentiment-rating-of-0-17.html.

In other news, Director Ann M. Veneman sold 835 shares of the firm’s stock in a transaction on Tuesday, September 5th. The stock was sold at an average price of $145.81, for a total value of $121,751.35. Following the completion of the sale, the director now owns 5,480 shares of the company’s stock, valued at approximately $799,038.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Julie O’neill sold 11,160 shares of the firm’s stock in a transaction on Monday, August 28th. The stock was sold at an average price of $140.00, for a total value of $1,562,400.00. Following the completion of the sale, the executive vice president now directly owns 26,704 shares of the company’s stock, valued at approximately $3,738,560. The disclosure for this sale can be found here. Insiders sold a total of 16,490 shares of company stock valued at $2,337,251 in the last three months. Insiders own 4.35% of the company’s stock.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Insider Buying and Selling by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.